1.
|
Frohman EM, Stuve O, Havrdova E, et al. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005 Oct;62(10):1519-30
|
3.
|
Rasova K, Brandejsky P, Havrdova E, Zalisova M, Rexova P. Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis? Mult Scler. 2005 Apr;11(2):213-21
|
5.
|
Frohman EM, Stuve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005 Oct;62(10):1519-30
|
6.
|
Fassas A, Passweg JR, Anagnostopoulos A,Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, La Nasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A for the Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation): Hematopoetic stem cell transplantation for multiple sclerosis: a retrospective study. J Neurol. 2002, vol 249, No 8, p. 1088-1097
|
7.
|
Stepan JJ, Havrdova E, Tyblova M, Horakova D, Ticha V, Novakova I, Zikan V. Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta. 2004 Oct;348(1-2):147-5
|